WiseGuyReports.Com Publish a New
Market Research Report On –“Alpha-Synuclein Pipeline Review Market 2016
Analysis,Growth,Trends and Forecast to 2021”.
COMPLETE
REPORT DETAILS @
https://www.wiseguyreports.com/reports/590042-alpha-synuclein-alphasyn-or-snca-pipeline-review-h1-2016
The, ‘Alpha-Synuclein (alphaSyn or SNCA) - Pipeline
Review, H1 2016’, provides in depth analysis on Alpha-Synuclein (alphaSyn
or SNCA) targeted pipeline therapeutics.
The report provides comprehensive information on the
Alpha-Synuclein (alphaSyn or SNCA), targeted therapeutics, complete with
analysis by indications, stage of development, mechanism of action (MoA), route
of administration (RoA) and molecule type. The report also covers the
descriptive pharmacological action of the therapeutics, its complete research
and development history and latest news and press releases. Additionally, the
report provides an overview of key players involved in Alpha-Synuclein
(alphaSyn or SNCA) targeted therapeutics development and features dormant and
discontinued projects.
For more information or any query mail at sales@wiseguyreports.com
The report features investigational drugs from
across globe covering over 20 therapy areas and nearly 3,000 indications. The
report is built using data and information sourced from Global Markets Direct’s
proprietary databases, company/university websites, clinical trial registries,
conferences, SEC filings, investor presentations and featured press releases
from company/university sites and industry-specific third party sources. Drug
profiles featured in the report undergoes periodic review following a stringent
set of processes to ensure that all the profiles are updated with the latest
set of information. Additionally, various dynamic tracking processes ensure
that the most recent developments are captured on a real time basis.
The report helps in identifying and tracking
emerging players in the market and their portfolios, enhances decision making
capabilities and helps to create effective counter strategies to gain competitive
advantage.
Note*: Certain sections in the report may be removed
or altered based on the availability and relevance of data.
GET
A SAMPLE REPORT @ https://www.wiseguyreports.com/sample-request/590042-alpha-synuclein-alphasyn-or-snca-pipeline-review-h1-2016
Scope
- The report provides
a snapshot of the global therapeutic landscape for Alpha-Synuclein (alphaSyn or
SNCA)
- The report reviews Alpha-Synuclein (alphaSyn or SNCA) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Alpha-Synuclein (alphaSyn or SNCA) targeted therapeutics and enlists all their major and minor projects
- The report assesses Alpha-Synuclein (alphaSyn or SNCA) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Alpha-Synuclein (alphaSyn or SNCA) targeted therapeutics
- The report reviews Alpha-Synuclein (alphaSyn or SNCA) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Alpha-Synuclein (alphaSyn or SNCA) targeted therapeutics and enlists all their major and minor projects
- The report assesses Alpha-Synuclein (alphaSyn or SNCA) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Alpha-Synuclein (alphaSyn or SNCA) targeted therapeutics
Reasons to buy
- Gain strategically
significant competitor information, analysis, and insights to formulate
effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Alpha-Synuclein (alphaSyn or SNCA)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Alpha-Synuclein (alphaSyn or SNCA) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Alpha-Synuclein (alphaSyn or SNCA)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Alpha-Synuclein (alphaSyn or SNCA) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Table Of Contents – Key Points
Table of
Contents 2
List of Tables 6
List of Figures 7
Introduction 8
Global Markets Direct Report Coverage 8
Alpha-Synuclein (alphaSyn or SNCA) Overview 9
Therapeutics Development 10
Alpha-Synuclein (alphaSyn or SNCA) - Products under Development by Stage of Development 10
Alpha-Synuclein (alphaSyn or SNCA) - Products under Development by Therapy Area 11
Alpha-Synuclein (alphaSyn or SNCA) - Products under Development by Indication 12
Alpha-Synuclein (alphaSyn or SNCA) - Pipeline Products Glance 13
Late Stage Products 13
Early Stage Products 14
Alpha-Synuclein (alphaSyn or SNCA) - Products under Development by Companies 15
Alpha-Synuclein (alphaSyn or SNCA) - Products under Development by Universities/Institutes 18
Alpha-Synuclein (alphaSyn or SNCA) - Therapeutics Assessment 20
Assessment by Monotherapy/Combination Products 20
Assessment by Mechanism of Action 21
Assessment by Route of Administration 22
Assessment by Molecule Type 24
Alpha-Synuclein (alphaSyn or SNCA) - Companies Involved in Therapeutics Development 26
AC Immune SA 26
AFFiRiS AG 27
BioArctic Neuroscience AB 28
Biogen, Inc. 29
NeuroPhage Pharmaceuticals, Inc. 30
Neuropore Therapies, Inc. 31
nLife Therapeutics, S.L. 32
Primary Peptides, Inc. 33
Prothena Corporation Plc 34
QR Pharma, Inc. 35
reMYND NV 36
Synovo GmbH 37
Alpha-Synuclein (alphaSyn or SNCA) - Drug Profiles 38
BAN-0805 - Drug Profile 38
Product Description 38
Mechanism Of Action 38
R&D Progress 38
BIIB-054 - Drug Profile 39
Product Description 39
Mechanism Of Action 39
R&D Progress 39
CLR-01 - Drug Profile 40
Product Description 40
Mechanism Of Action 40
List of Tables 6
List of Figures 7
Introduction 8
Global Markets Direct Report Coverage 8
Alpha-Synuclein (alphaSyn or SNCA) Overview 9
Therapeutics Development 10
Alpha-Synuclein (alphaSyn or SNCA) - Products under Development by Stage of Development 10
Alpha-Synuclein (alphaSyn or SNCA) - Products under Development by Therapy Area 11
Alpha-Synuclein (alphaSyn or SNCA) - Products under Development by Indication 12
Alpha-Synuclein (alphaSyn or SNCA) - Pipeline Products Glance 13
Late Stage Products 13
Early Stage Products 14
Alpha-Synuclein (alphaSyn or SNCA) - Products under Development by Companies 15
Alpha-Synuclein (alphaSyn or SNCA) - Products under Development by Universities/Institutes 18
Alpha-Synuclein (alphaSyn or SNCA) - Therapeutics Assessment 20
Assessment by Monotherapy/Combination Products 20
Assessment by Mechanism of Action 21
Assessment by Route of Administration 22
Assessment by Molecule Type 24
Alpha-Synuclein (alphaSyn or SNCA) - Companies Involved in Therapeutics Development 26
AC Immune SA 26
AFFiRiS AG 27
BioArctic Neuroscience AB 28
Biogen, Inc. 29
NeuroPhage Pharmaceuticals, Inc. 30
Neuropore Therapies, Inc. 31
nLife Therapeutics, S.L. 32
Primary Peptides, Inc. 33
Prothena Corporation Plc 34
QR Pharma, Inc. 35
reMYND NV 36
Synovo GmbH 37
Alpha-Synuclein (alphaSyn or SNCA) - Drug Profiles 38
BAN-0805 - Drug Profile 38
Product Description 38
Mechanism Of Action 38
R&D Progress 38
BIIB-054 - Drug Profile 39
Product Description 39
Mechanism Of Action 39
R&D Progress 39
CLR-01 - Drug Profile 40
Product Description 40
Mechanism Of Action 40
Continue……
For more information or any query mail at
sales@wiseguyreports.com
CHECK DISCOUNT ON THIS REPORT @ https://www.wiseguyreports.com/check-discount/590042-alpha-synuclein-alphasyn-or-snca-pipeline-review-h1-2016
Contact
Us:
NORAH TRENT
Partner
Relations & Marketing Manager
sales@wiseguyreports.com
www.wiseguyreports.com
Ph:
+1-646-845-9349 (US)
Ph:
+44 208 133 9349 (UK)
No comments:
Post a Comment